Fig. 1.

Figure depicting the assessment of olaparib efficacy in 139 Veterans who received olaparib as part of their treatment regimen. We began by estimating the rate of tumor growth or g-rate in the 139 Veterans while they received olaparib and the treatment before olaparib. Next, we divided 0.693, the natural logarithm of 2, by the rate of tumor growth, g-rate, and estimated the tumor's doubling time (DT). Finally, the tumor DT while receiving olaparib was divided by the DT on the therapy prior to olaparib, allowing us to estimate the ratio of DTs. We chose a ratio of 1 as the threshold for activity and confirmed its contribution [see Fig. 2]. The downward pointing arrow identifies a DT ratio of 1. All those to the right of this had a DT ratio$\ge$ 1 meaning olaparib efficacy was superior to the efficacy of the previous therapy evidenced by slower tumor growth and a prolonged DT. Note that many of these ratios were very high indicative of marked slowing of tumor growth by olaparib in Veterans who received the drug often as their third or fourth line of treatment, as shown by the green bars describing the number of prior therapies (see Table 1). Also shown are the HRR genes harboring mutations, the drug used just prior to olaparib, the PSA value when olaparib was started, and the race of the Veteran.